These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 1243822

  • 21. High-resolution chromatography provides the answer to the 15-year-old problem of azaribine toxicity.
    Kovach JS.
    J Lab Clin Med; 1977 Nov; 90(5):771-2. PubMed ID: 578520
    [No Abstract] [Full Text] [Related]

  • 22. Azaribine, homocystinemia, and thrombosis.
    Shupack JL, Grieco AJ, Epstein AM, Sansaricq C, Snyderman SE.
    Arch Dermatol; 1977 Sep; 113(9):1301-2. PubMed ID: 578401
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Therapy of psoriasis 1975.
    Van Scott EJ.
    JAMA; 1976 Jan 12; 235(2):197-8. PubMed ID: 946030
    [No Abstract] [Full Text] [Related]

  • 27. Nucleoside analogs in the treatment of nonneoplastic diseases.
    Calabresi P, Doolittle CH, Heppner GH, McDonald CJ.
    Ann N Y Acad Sci; 1975 Aug 08; 255():190-201. PubMed ID: 1059354
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Psoriasis: clinical aspects and management.
    Rees RB.
    Cutis; 1976 Aug 08; 18(2):231-5. PubMed ID: 828093
    [No Abstract] [Full Text] [Related]

  • 31. Changes in serum and urine amino acids in patients with progressive systemic sclerosis treated with 6-azauridine triacetate.
    Slavik M, Lovenberg W, Keiser HR.
    Biochem Pharmacol; 1973 Jun 01; 22(11):1295-300. PubMed ID: 4727783
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Azaribine-homocystinemia-thrombosis in historical perspective.
    Drell W, Welch AD.
    Pharmacol Ther; 1989 Jun 01; 41(1-2):195-206. PubMed ID: 2469090
    [No Abstract] [Full Text] [Related]

  • 37. Postmarketing surveillance of new drugs: II. Case studies.
    Wardell WM, Tsianco MC, Anavekar SN, Davis HT.
    J Clin Pharmacol; 1979 Apr 01; 19(4):169-84. PubMed ID: 374427
    [No Abstract] [Full Text] [Related]

  • 38. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy.
    Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ.
    Arch Dermatol; 1995 Jul 01; 131(7):791-5. PubMed ID: 7611794
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.